Stay updated with breaking news from Progressive Multifocal. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Sandoz's natalizumab-sztn injection (Tyruko) is on par with Biogen's Tysabri (natalizumab) for treatment of relapsing forms of MS, the FDA said in approving the first biosimilar to treat MS.
/PRNewswire/ -- Cellevolve Bio, Inc. ("the Company" or "Cellevolve"), a clinical stage development and commercialization platform company focused on cell...
/PRNewswire/ -- Cellevolve Bio, Inc. ("the Company" or "Cellevolve"), a development and commercialization platform company focused on cell therapies, today...
IPO Alert: Inhibikase Therapeutics (IKT) BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Inhibikase Therapeutics is scheduled to make its debut on the Nasdaq Global Select Market today (December 23), under the ticker symbol 'IKT.' Atlanta, Georgia-based Inhibikase Therapeutics is a clinical stage pharmaceutical company developing therapeutics kinase inhibitors for Parkinson's disease and related disorders. The company has offered to sell 1.8 million shares of its common stock at a price of $10 each. The underwriters have an option for a period of 45 days to purchase up to an additional 270 thousand shar...